XBIO (Xenetic Biosciences) Marketable Securities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBIO Xenetic Biosciences Inc XBIO
84 GF Score
Price $3.28
GF Value $3.75
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Marketable Securities?

Xenetic Biosciences XBIO -0.30% 84 Marketable Securities is $0.00 Mil as of Jun. 2026. GuruFocus rates XBIO with a GF Score™ of 84/100 and a GF Value™ of $3.75 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Xenetic Biosciences's Marketable Securities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Xenetic Biosciences  (NAS:XBIO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Xenetic Biosciences Marketable Securities Related Terms

Xenetic Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences Marketable Securities Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Xenetic Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBIO
84GF Score
Xenetic Biosciences Inc XBIO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Xenetic Biosciences (XBIO) has a Marketable Securities of $0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Marketable Securities too high?
Xenetic Biosciences' current Marketable Securities is $0.00 Mil. Overall, Xenetic Biosciences has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Marketable Securities compare to ADIL and PULM?
Xenetic Biosciences' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.75, compared to a current price of $3.28 — trading 12.5% below its estimated fair value. The current Marketable Securities is $0.00 Mil. Xenetic Biosciences' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Marketable Securities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $3.28 is trading 12.5% below its estimated GF Value™ of $3.75. GuruFocus considers Xenetic Biosciences to be Modestly Undervalued.

Key valuation signals for XBIO:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $3.75 vs. price of $3.28 (12.5% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
84GF Score

Get the complete analysis for XBIO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.28
Price
$3.75
GF Value